Navigation Links
Nutraceutical Reports Q3 Results
Date:7/31/2008

PARK CITY, Utah, July 31 /PRNewswire-FirstCall/ -- Nutraceutical International Corporation (Nasdaq: NUTR) today reported results for the fiscal 2008 third quarter ended June 30, 2008. Net sales for the fiscal 2008 third quarter were $40.5 million compared to $38.7 million for the same quarter of fiscal 2007. For the third quarter of fiscal 2008, net income was $2.9 million, or $0.26 diluted earnings per share, compared to net income of $2.9 million, or $0.25 diluted earnings per share, for the same quarter of fiscal 2007.

Net sales for the nine months ended June 30, 2008 were $126.0 million compared to $116.6 million for the same period in fiscal 2007. For the nine months ended June 30, 2008, net income was $10.4 million, or $0.93 diluted earnings per share, compared to net income of $10.4 million, or $0.92 diluted earnings per share, for the same period of fiscal 2007.

Operating cash flow for the nine months ended June 30, 2008 was $14.4 million compared to $15.6 million for the same period of fiscal 2007. This operating cash flow, combined with net borrowings of $10.0 million, was used to invest $14.1 million in property and equipment, $5.9 million in acquisitions of branded natural product businesses and $4.2 million in repurchases of common stock.

Bill Gay, chairman and chief executive officer, commented, "The growth in net sales for our fiscal 2008 third quarter came from the integration of our fiscal 2007 and 2008 acquisitions into our brands. Operational synergies from manufacturing have enabled us to increase gross profit margins and provide continued strong operating cash flows. Raw material costs have increased but our focus on sourcing has allowed us to mitigate the impact to date. We continue to invest in
'/>"/>

SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
2. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
3. Berkeley Premium Nutraceuticals Pushes Forward
4. Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City
5. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
6. Nutraceutical Reports Fiscal 2008 Q1 Results
7. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
8. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
9. Nutraceutical Reports 2007 Fiscal Year End Results
10. New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs
11. New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , , PEMBROKE, Bermuda, Dec. 4 /PRN...ny Holdings, Ltd (NYSE: AWH ) today announced th...Officer, and Jack Sennott, Executive Vice,Presiden...esenting at the 2009,Goldman Sachs U.S. Financial ...s Conference Center in New York City on Tuesday, D...
(Date:12/4/2009)... , , MADISON HEIGHTS, Mich., Dec...urities Review Committee of BetterInvesting Magaz... ) as its February 2010 "Stock to Study" and C.R....Undervalued Stock" for investors, informational an...rgan because of growth opportunities involving its...
(Date:12/4/2009)... , Late recurrence is a risk for some pediatric c...the central nervous system, according to a new stu...the National Cancer Institute . , This study was...ate recurrence (after 5 years and up to 20 years) ...i-Masker, M.D., of the Aflac Cancer Center and Blo...
(Date:12/4/2009)... , More than 15 million Americans are recruited...ing to the Alliance for Human Research Protection ...ticipation. , Research institutions view pay...xpenses; not as compensation for potential risks r... new study finds that volunteers have a very diffe...
(Date:12/4/2009)... Increasing exercise, water and fruit consumptio...IDAY, Dec. 4 (HealthDay News) -- Increased exercis...among the most effective weight control strategies...ers surveyed 130 adolescents about their weight-co...ad succeeded in losing weight and 68 had not. The ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...genital Heart Disease published recently in the Eu...ty of adult heart care and the extent of its defic...improvement in the treatment of pediatric heart di...of the patients and list the deficient areas. 71 c...
... by researchers at Columbia University Medical Cen... rates and adherence to cancer treatment, //it has...had stopped their chemotherapy. More specifically,...efore completion. Non-compliance rates in th...
...rs at University of Manchester now reveals that sp...iseases, Vascular Dementia and Alzheimer's disease...sh Medical Journal (BMJ). This finding could e...d vascular dementia can account for a major propor...
...n 2004 the sales of Celebrex was $3.3 billion worl...g causing heart attacks the company stopped advert...he consumer ad market in hopes of reviving sales o...oost it sales. Each ad includes a boldface warnin...
...quently among children. It is one of the diseases ...ow 3 months of age//. Hence Dr. Lawrence S. Eichen...an Diego and colleagues came up with the fluticaso...en compared to ointments and creams. It is very he...
...ssion of senile amyloidosis to offspring from affe...om mother to child// have been raised. Details abo...is in offspring of mice with AApoAII amyloidosis,'...including amyloidosis. Amyloidosis occurs when cel...
Other Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2Health News:Doubts About In UteroTransmission Of Senile Amyloidosis 2
(Date:12/3/2009)...DOYLESTOWN, Pa., Dec. 3 ...ation, (Nasdaq: QGLY ) www.quigleyco.com announ...ation of its opportunities to develop prescription... that it is in its best interests to focus primari... include but are not limited to its Cold-EEZE®...
(Date:12/3/2009)..., WARRENDALE, Pa., Dec. 3 Radiol... injection-record integration capabilities at the ...n Chicago. The Connect.PACS(TM) product, enabli... its kind, is the latest release in the company,s ... ,, (Photo: http://www.newscom.com/cgi-bin/...
(Date:12/3/2009)..., HOERSHOLM, Denmark and SAN DIEGO, Californi... Successfully Inhibits miR-122, a microRNA Importa...ificantly Reducing Hepatitis C,Virus in the Bloods...,Hepatitis C Virus , - SPC3649 Demonstrat...nd,No Serious Adverse Events in the Treated Animal...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 1Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 2Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 3Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 4Genes May Raise Risk of Neuroblastoma in Kids 49265 1Genes May Raise Risk of Neuroblastoma in Kids 49265 2Genes May Raise Risk of Neuroblastoma in Kids 49265 3Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 1Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 2
...AL GABLES, Fla., Jan. 9 Catalyst,Pharmaceutical P...al company that,acquires, in-licenses, develops an...ent of drug addiction, announced today that it has...e II trial evaluating CPP-109 for the treatment,of...ormulation of vigabatrin,being developed as a trea...
... Switzerland, Jan. 9 ESBATech AG, a leading develo...nced the initiation of the Phase I/IIa clinical de...ESBA105 in osteoarthritis (OA). This double-blind,...al study is designed to investigate the safety, to...ed locally via intra-articular administration to p...
Other Medicine Technology:Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 2Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: